Aarti Drugs: Inspection by USFDA of formulation facility of subsidiary Company, Pinnacle Life Science Private Limited'

What happened

Aarti Drugs (AARTIDRUGS) filed a disclosure with the exchanges on 6 November 2026 at 05:08 PM titled "Inspection by USFDA of formulation facility of subsidiary Company, Pinnacle Life Science Private Limited'".

Company snapshot

Aarti Drugs is a small-cap company in the Healthcare sector, with a market value of about ₹4,160 crore.

The stock last traded at ₹455.8, against a 52-week range of ₹319–₹534 (14.6% below the high).

Before this filing the shares had moved +9.8% over the month and +10.9% over three months. Average daily turnover over the last 20 sessions was about ₹42.84 crore.

Promoters held 54.07% at the end of Q2 FY27, down 0.36% points from the previous quarter; 2.51% of promoter shares were pledged. Foreign institutions owned 2.26% and domestic institutions 10.24%.

What history shows

BCEIE has no earlier approval filing from this company on record since May 2026.

Across 129 similar disclosures by other Healthcare companies, shares moved +0.5% on average the next day and +1.1% over five days; 53% of them rose the next day.

Market-wide, 1,583 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 48% rising.

Past reactions describe what happened before; they are not a forecast.

In the news

Recent coverage elsewhere (links open the original publisher):

• Aarti Drugs Q2 Results: Net profit soars 83% on stronger margins, revenue growth — CNBC TV18, 3 Nov 2026
• Earnings call transcript: Aarti Drugs posts record Q2 FY 2027 revenue, shares slip By Investing.com — Investing.com India, 4 Nov 2026
• Aarti Drugs Q2 2027 Earnings Call Is Live — TradingView, 4 Nov 2026
• Aarti Drugs Limited reports ₹82.77 crore Q2 PAT, ₹826.24 crore revenue — Multibagg AI, 3 Nov 2026
• Aarti Drugs Q2 FY27 Profit Jumps 83% on API, Formulation Growth — eHealth Magazine, 2 Nov 2026

Source

• Exchange filing (PDF)